PLG and lung carcinoma: Indeed, in this study we demonstrated that blocking ENO1 by treatment with an ENO1-specific Ab or suppressing ENO1 expression by treatment with a specific shRNA plasmid reduces plasmin and MMP2/9 activation, ECM degradation, and invasion capacity in lung cancer cells.